Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO1996039113 - ORAL ADMINISTRATION OF PNEUMOCOCCAL ANTIGENS

Publication Number WO/1996/039113
Publication Date 12.12.1996
International Application No. PCT/IB1996/001051
International Filing Date 31.05.1996
Chapter 2 Demand Filed 17.12.1996
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/09 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
09Streptococcus
CPC
A61K 39/092
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus; , streptococcus
092Streptococcus
Applicants
  • UAB RESEARCH FOUNDATION [US]/[US]
Inventors
  • BRILES, David, E.
  • McDANIEL, Larry, S.
  • YAMAMOTO, Masafumi
  • KIYONO, Hiroshi
Agents
  • FROMMER, William, S.
Priority Data
08/458,39902.06.1995US
08/482,98107.06.1995US
08/657,75130.05.1996US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ORAL ADMINISTRATION OF PNEUMOCOCCAL ANTIGENS
(FR) ADMINISTRATION PAR VOIE ORALE D'ANTIGENES PNEUMOCOCCIQUES
Abstract
(EN)
Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, wich can lead to elimination of disease from the population as a whole.
(FR)
L'administration par voie orale ou perorale, y compris par voie intragastrique, de pneumocoques tués, de lysat de pneumocoques et de protéine A de la face membranaire du pneumocoque (PsaA) isolée et purifiée ainsi que de fragments immunogènes de celle-ci, notamment lorsqu'elle s'effectue en compagnie d'un adjuvant tel que la toxine cholérique, protège l'hôte, animal ou humain, contre l'infection pneumococcique, y compris une colonisation pneumococcique, et contre une infection généralisée telle que la septicémie. La possibilité d'obtenir une protection contre la colonisation pneumococcique chez un hôte évite tout hébergement par des individus immunisés, ce qui est susceptible de conduire à l'éradication de la maladie dans l'ensemble d'une population.
Also published as
FI974376
NO19975522
Latest bibliographic data on file with the International Bureau